(Adnkronos) - I pazienti colpiti da mielofibrosi, tumore particolarmente aggressivo del sangue che colpisce il midollo osseo, impedendogli di formare correttamente globuli rossi, globuli bianchi e piastrine, hanno oggi a disposizione una nuova opzione terapeutica, efficace anche contro l’anemia, una delle complicazioni più serie della malattia. Si tratta di momelotinib, inibitore selettivo delle proteine JAK1 e JAK2 e del recettore dell'activina A di tipo 1 (Acvr1), a cui l’Agenzia italiana del Farmaco, Aifa, ha concesso la rimborsabilità.
Category
🗞
NewsTranscript
00:00Myelofibrosis is a rare blood tumor, particularly aggressive, hits the bone marrow, preventing it from correctly forming red blood cells, white blood cells and platelets.
00:14Every year in Italy, about 350 people receive this diagnosis.
00:19It is an important disease because the global average life expectancy of patients with myelofibrosis is estimated to still be around 6-7 years, although the introduction and use of inhibitors has led to an improvement in the global survival of the disease.
00:37Patients with myelofibrosis have today available a new therapeutic option, it is Momelotinib, to which the Italian Pharmaceutical Agency has granted reimbursement.
00:47Its effectiveness, also against anemia, one of the most serious complications of the disease, has been verified in clinical studies Simplify I and II and Momentum.
00:56Globally, the effectiveness against myelitis, symptoms and hemoglobin has been documented in these three studies.
01:03From a tolerability point of view, we can say that the pharmacist is very tolerant, there are no adverse events to report with particular stress,
01:15it is very important, as with other inhibitors, to pay attention to the risk of infection, because the inhibition also leads to a reduction of some subtypes of lymphocytes that can predispose to certain infections.
01:28The drug changes the history of the disease and offers a better quality of life to patients.
01:34The arrival of Momelotinib patients, who can control aspects of the disease that other inhibitory drugs cannot, is the result of the commitment of GSK in onco-hematology.
02:00Momelotinib has the characteristic of controlling aspects of the disease, in particular anemia, which are aspects that are not controlled by other drugs of the same category.
02:11Why is it so important? Because controlling aspects such as anemia means giving the patient the opportunity to regain control of his life, to be able to do most of his daily activities, if not all of them, to depend less on the support of the caregiver and to be able to enjoy the affections that surround him more.